DSNKY
HealthcareDaiichi Sankyo Company, Limited · Drug Manufacturers - General · $34B
What is Daiichi Sankyo Company, Limited?
Daiichi Sankyo is a global pharmaceutical company headquartered in Tokyo, Japan, with a broad portfolio spanning oncology, cardiovascular, and metabolic diseases. Its antibody drug conjugate platform has drawn significant international attention in recent years.
Daiichi Sankyo discovers, develops, manufactures, and commercializes prescription medicines and consumer health products worldwide. Revenue comes primarily from prescription pharmaceuticals sold through hospital and retail pharmacy channels, supplemented by over-the-counter consumer brands. The company's oncology pipeline — anchored by its HER2-targeting antibody drug conjugate — has become a central growth driver, while established cardiovascular and diabetes franchises provide a stable revenue base across Japan and international markets.
The company was formed in 2008 through a merger, with headquarters in Tokyo, Japan.
- Trastuzumab deruxtecan — HER2-targeting antibody drug conjugate for cancer
- Edoxaban — oral anticoagulant for cardiovascular conditions
- Mirogabalin — treatment for peripheral neuropathic pain
- Teneligliptin and canagliflozin — type 2 diabetes therapies
- Loxonin S and Minon — consumer OTC analgesic and skincare brands
Is DSNKY a Good Stock to Buy?
UQS Score rates DSNKY as Good overall, reflecting a balanced profile with notable strengths in risk management and valuation.
The Risk pillar stands out as Strong, suggesting the company carries a relatively conservative financial and operational risk profile compared with sector peers. Valuation is rated Attractive, meaning the stock appears reasonably priced relative to its fundamentals — a combination that can appeal to quality-conscious investors. Growth is rated Good, supported by the expanding global uptake of its oncology pipeline.
Quality and Moat are both rated Neutral, indicating these dimensions are in line with — but not clearly ahead of — the broader pharmaceutical peer group.
See the exact pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does DSNKY pay dividends?
Yes — Daiichi Sankyo Company, Limited pays a dividend.
Daiichi Sankyo pays a regular dividend, consistent with the practice of many established Japanese pharmaceutical companies that return capital to shareholders alongside reinvestment in R&D. The dividend reflects the company's relatively stable cash generation from its mature product franchises. Investors seeking income alongside pharmaceutical exposure may find this cadence relevant to their screening criteria.
When does DSNKY report earnings?
Daiichi Sankyo reports financial results on a quarterly cadence, as is standard for internationally listed pharmaceutical companies.
Results in recent periods have been shaped by the global rollout of its oncology pipeline alongside steady contributions from cardiovascular and diabetes products. Currency movements between the Japanese yen and major international currencies can influence reported figures meaningfully.
For the most recent quarter's results and guidance updates, visit Daiichi Sankyo's official investor relations page.
DSNKY Price History
-24.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Daiichi Sankyo Company, Limited?
Based on Daiichi Sankyo Company, Limited's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
DSNKY Long-term Outlook
The Growth pillar rated Good points to a company with meaningful near-to-medium-term expansion potential, driven largely by its oncology franchise gaining traction across global markets. The Strong Risk rating suggests this growth is pursued within a relatively disciplined financial framework. However, Neutral Quality and Moat ratings indicate that durable competitive advantages are not yet firmly established at a level that separates Daiichi Sankyo decisively from large-cap pharmaceutical peers.
Growth drivers
- Expanding global adoption of its HER2-targeting antibody drug conjugate across multiple cancer indications
- Licensing and co-commercialization partnerships that extend geographic reach without proportional capital outlay
- Pipeline diversification into additional oncology and specialty disease areas
Key risks
- Patent expiration and biosimilar competition for established cardiovascular and diabetes products
- Regulatory and clinical trial risk inherent in a pipeline-dependent growth strategy
- Yen-to-dollar and yen-to-euro currency fluctuations affecting international revenue translation
DSNKY vs Peers
Within the large-cap global pharmaceutical space, Daiichi Sankyo competes with several well-capitalized peers across oncology, cardiovascular, and specialty medicine.
Biogen is concentrated in neuroscience and rare neurological diseases, whereas Daiichi Sankyo's growth is anchored in oncology and cardiovascular medicine.
GSK competes across vaccines and specialty medicines globally, giving it a broader therapeutic footprint but also a different risk profile than Daiichi Sankyo's oncology-led strategy.
Sanofi's scale in immunology and rare diseases contrasts with Daiichi Sankyo's sharper focus on antibody drug conjugate technology as a primary growth engine.
Frequently Asked Questions
What does Daiichi Sankyo do?
Daiichi Sankyo researches, develops, manufactures, and sells pharmaceutical products worldwide. Its portfolio spans prescription oncology medicines, cardiovascular treatments, diabetes therapies, and consumer health brands sold primarily in Japan and international markets.
Does DSNKY pay dividends?
Yes, Daiichi Sankyo pays a regular dividend. This is consistent with the capital return practices of many established Japanese pharmaceutical companies. Investors should check the company's investor relations page for the current dividend schedule and payment history.
When does DSNKY report earnings?
Daiichi Sankyo reports on a quarterly cadence, typical for internationally listed pharmaceutical companies. For the most current earnings calendar and results, refer to the company's official investor relations page rather than relying on third-party estimates.
Is DSNKY a good stock to buy?
UQS Score rates DSNKY as Good overall, with a Strong Risk profile and Attractive Valuation standing out as positives. Quality and Moat are Neutral. Whether it fits your portfolio depends on your own investment criteria — the full pillar breakdown is available to UQS Pro members.
Is DSNKY overvalued?
The UQS Valuation pillar for DSNKY is rated Attractive, suggesting the stock does not appear expensive relative to its fundamental profile. Valuation is one of five pillars — viewing it alongside Quality, Growth, Moat, and Risk gives a more complete picture.
How does DSNKY compare to its competitors?
Compared with large-cap peers like Biogen, GSK, and Sanofi, Daiichi Sankyo is more concentrated in oncology — particularly antibody drug conjugate technology — and cardiovascular medicine. Its Attractive Valuation and Strong Risk rating may differentiate it within a peer group where valuations vary widely.
What is DSNKY's market cap bracket?
Daiichi Sankyo is classified as a large-cap company, placing it among the larger publicly traded pharmaceutical companies globally. Large-cap status generally implies greater liquidity and institutional coverage than mid- or small-cap peers.
Who founded Daiichi Sankyo?
Daiichi Sankyo was formed in 2008 through the merger of Daiichi Pharmaceutical and Sankyo Company, both long-established Japanese pharmaceutical firms. Detailed founding history for each predecessor company is widely available through public sources and the company's own corporate history page.
Is DSNKY a long-term quality indicator?
From a quality-scoring perspective, DSNKY's Good overall UQS Score — supported by Strong Risk and Good Growth — suggests a company with a reasonable long-term fundamental foundation. Neutral Moat and Quality ratings indicate areas where the durability of competitive advantage is still developing. Pro members can view the complete analysis.
What is the main competitive advantage of Daiichi Sankyo?
Daiichi Sankyo's most distinctive asset is its antibody drug conjugate technology platform, which has attracted major global licensing partnerships. This proprietary approach to delivering cancer-fighting agents directly to tumor cells represents a differentiated capability within the oncology landscape.
What sector does DSNKY belong to?
DSNKY operates in the Healthcare sector, specifically within the pharmaceutical industry. The company spans prescription medicines, specialty biologics, and consumer health products, giving it exposure to multiple sub-segments of global healthcare spending.
Is DSNKY a growth stock or value stock?
Based on UQS pillar labels, DSNKY shows characteristics of both — Growth is rated Good, reflecting pipeline-driven expansion potential, while Valuation is rated Attractive, suggesting it is not priced at a significant premium. This combination may appeal to investors seeking growth without paying a steep valuation multiple.
Unlock Full DSNKY Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact score for all five UQS pillars
- ✓Access underlying financial metrics driving each rating
- ✓Compare DSNKY against pharmaceutical sector peers
- ✓Track Quality, Moat, and Risk changes over time
- ✓Screen for similar Attractive Valuation healthcare stocks
- ✓Get the complete analyst-style breakdown in one view
Pro Analysis
DSNKY — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | 62.9 | 47.2 | 48.0 | 64.5 | 94.5 | 80.3 | -0.1 |
| Jun 9, 2026 | 63.0 | 47.2 | 48.0 | 64.5 | 94.5 | 80.5 | -0.1 |
| Jun 8, 2026 | 63.1 | 47.2 | 48.0 | 64.5 | 94.5 | 81.1 | -0.1 |
| Jun 6, 2026 | 63.2 | 47.2 | 48.0 | 64.9 | 94.5 | 81.4 | -0.3 |
| Jun 5, 2026 | 63.5 | 47.2 | 48.0 | 66.8 | 94.5 | 81.1 | +0.1 |
| Jun 4, 2026 | 63.4 | 47.2 | 48.0 | 66.8 | 94.5 | 80.4 | +0.1 |
| Jun 3, 2026 | 63.3 | 47.2 | 48.0 | 66.8 | 94.5 | 79.7 | +5.4 |
| Jun 2, 2026 | 57.9 | 46.4 | 48.0 | 38.4 | 94.5 | 83.2 | -5.5 |
| Jun 1, 2026 | 63.4 | 47.2 | 48.0 | 66.8 | 94.5 | 80.4 | 0.0 |
| May 31, 2026 | 63.4 | 47.2 | 48.0 | 67.4 | 94.5 | 79.3 | -0.7 |
DSNKY — Pillar Breakdown
Quality
— 47.2/100 (25%)Daiichi Sankyo Company, Limited has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 64.5/100 (20%)Daiichi Sankyo Company, Limited demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 94.5/100 (15%)Daiichi Sankyo Company, Limited carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 83.3/100 (15%)Daiichi Sankyo Company, Limited appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 48/100 (25%)Daiichi Sankyo Company, Limited possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for DSNKY.
Score Composition
Financial Data
More Stock Analysis
How is the DSNKY UQS Score Calculated?
The UQS (Unified Quality Score) for Daiichi Sankyo Company, Limited is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Daiichi Sankyo Company, Limited's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Daiichi Sankyo Company, Limited is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.